Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00467-017-3584-9 http://scihub22266oqcxt.onion/10.1007/s00467-017-3584-9 C5368203!5368203!28194574     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pediatr+Nephrol 2017 ; 32 (5): 893-6 Nephropedia Template TP {{tp|p=28194574|t=2017. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease |pdf=|usr=}}{{28194574}} gab.com Text Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease JO: Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28194574 #FOAvip Background: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. Case diagnosis/treatment: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. Conclusion: Tolvaptan may be a useful treatment for severe neonatal PKD. Twit Text FOAVip Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease ????Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28194574 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28194574 #FOAvip English Wikipedia <ref>{{Cite pmid|28194574}}</ref> Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease #MMPMID28194574 Gilbert RD; Evans H; Olalekan K; Nagra A; Haq MR; Griffiths M Pediatr Nephrol 2017[]; 32 (5): 893-6 PMID28194574show ga Background: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. Case diagnosis/treatment: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. Conclusion: Tolvaptan may be a useful treatment for severe neonatal PKD. äTolvaptan treatment for severe neonatal autosomal-dominant polycystic (epmc).pdf DeepDyve Pubget Overpricing